Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product...
News
Venus Concept Announces CE Mark for Venus Versa Pro in Europe
TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of...
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific...
Bitech Technologies Appoints Sid Sung as Its New Chief Innovation Officer to Lead the Digital Revolution in the Renewable Energy Industry
Newport Beach, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation , (“the Company” or “Bitech”) a global technology...
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin...
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin...
CloudMD and Bristol Health Medical Group Announce the Launch of the Breakthrough Deviceless Remote Patient Monitoring Program
Bristol Health Embraces Innovation by Launching its Inaugural Remote Patient Monitoring Program Utilizing CloudMD's HealthyLYF PlatformVancouver, British Columbia--(Newsfile Corp. -...
IRLAB has Completed a Successful End-of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESSWIRE / February 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 22 February 2024 - IRLAB Therapeutics...
Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Director Share PurchaseLONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical...
Cantargia Publishes Year-End Report for 2023
LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced...
Cedar Grove Chiropractic Office Introduces Innovative TRT Softwave Therapy to Enhance Patient Care
The Chiropractic Source, the leading chiropractic office in Cedar Grove, NJ, is proud to announce the introduction of TRT Softwave...
Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.
BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a...
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the...
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology...
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45%...
Modular Medical Announces Closing of $10 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a...
World-Leading Schizophrenia Expert Dr. Jeffrey A. Lieberman Unravels the Mysteries of Schizophrenia on The People’s Pharmacy
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / Millions of Americans live with schizophrenia, a complex and long...